Compare Organon & Co. Common Stock (OGN) vs State Street Corporation Common Stock (STT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs State Street Corporation Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while State Street Corporation Common Stock trades at $166.95 (market cap $47.83B). The key difference: State Street Corporation Common Stock is far larger — about 13.2× Organon & Co. Common Stock's market cap, and State Street Corporation Common Stock pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and State Street Corporation Common Stock for 2 Days on average.
| OGN | STT | |
|---|---|---|
Market Cap | $3.62B | $47.83B |
Volume | 2,892,999 | 2,907,463 |
Sector | Health | Financials |
52-Week High | $13.81 | $194.26 |
52-Week Low | $5.70 | $111.37 |
Typical Hold Time | 0 Days | 2 Days |
Enterprise Value | $11.04B | $74.34B |
Dividend Yield | 0.58% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
State Street (STT) trades at $173.99, down 0.54% with bearish technical signals despite strong Q3 2026 earnings beat. The stock faces headwinds from a revenue miss and ongoing investigation, though fundamentals show robust profitability with 22.95% net margin and consistent earnings growth. Analyst consensus remains positive with $183.55 price target, but technical indicators show selling pressure with support at $172.
Outlook is mixed with strong fundamentals supporting long-term value, but near-term risks from the securities investigation and bearish technicals create uncertainty. The 13% revenue growth and record AUM provide upside potential, though investors should monitor legal developments and expense trends that could impact sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About State Street Corporation Common Stock
State Street provides investment servicing, custody, and asset management services to institutional investors. Its asset management business includes the SPDR ETF range.
Read more on STT →
